CStone Pharmaceuticals Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
135
- Stock Symbol
-
02616
- Share Price
-
$0.36
- (As of Tuesday Closing)
CStone Pharmaceuticals General Information
Description
CStone Pharmaceuticals is engaged in the development and commercialization of tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.
Contact Information
Website
www.cstonepharma.comCorporate Office
- Xinghu Street Suzhou Industrial Park
- C1 Building, Number 218
- Suzhou, Jiangsu 215123
- China
Corporate Office
- Xinghu Street Suzhou Industrial Park
- C1 Building, Number 218
- Suzhou, Jiangsu 215123
- China
CStone Pharmaceuticals Stock Performance
As of 22-Apr-2025, CStone Pharmaceuticals’s stock price is $0.36. Its current market cap is $482M with 1.36B shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.36 | $0.32 | $0.11 - $0.50 | $482M | 1.36B | 6.69M |
CStone Pharmaceuticals Financials Summary
As of 31-Dec-2024, CStone Pharmaceuticals has a trailing 12-month revenue of $56.7M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 311,894 | 311,894 | 264,594 | 558,753 |
| Revenue | 56,750 | 56,750 | 65,562 | 71,477 |
| EBITDA | (5,422) | (5,422) | (45,529) | (126,048) |
| Net Income | (12,711) | (12,711) | (51,907) | (134,037) |
| Total Assets | 190,883 | 190,883 | 234,461 | 237,477 |
| Total Debt | 48,763 | 48,763 | 51,272 | 41,496 |
CStone Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CStone Pharmaceuticals Comparisons
Industry
Financing
Details
CStone Pharmaceuticals Competitors (12)
One of CStone Pharmaceuticals’s 12 competitors is Alphamab Oncology, a Formerly VC-backed company based in Suzhou, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alphamab Oncology | Formerly VC-backed | Suzhou, China | ||||
| Abbisko Therapeutics | Formerly VC-backed | Shanghai, China | ||||
| Innovent Biologics | Formerly PE-Backed | Shanghai, China | ||||
| BeiGene | Formerly PE-Backed | Beijing, China | ||||
| BoomRay Pharmaceuticals | Venture Capital-Backed | Suzhou, China |
CStone Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CStone Pharmaceuticals Patents
CStone Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220387417-A1 | Pharmaceutical combination and use thereof | Pending | 11-Nov-2019 | ||
| CA-3160526-A1 | Pharmaceutical combination and use thereof | Pending | 11-Nov-2019 | ||
| AU-2020383580-A1 | Pharmaceutical combination and use thereof | Pending | 11-Nov-2019 | ||
| JP-2023500385-A | Pharmaceutical combinations and uses thereof | Pending | 11-Nov-2019 | ||
| EP-4031179-A1 | Pharmaceutical combination and use thereof | Pending | 11-Nov-2019 | A61K31/47 |
CStone Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CStone Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CStone Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated August, 29, 2024
39.84 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Pharmaceuticals
Subindustry
of 430
Rank
Percentile
CStone Pharmaceuticals FAQs
-
When was CStone Pharmaceuticals founded?
CStone Pharmaceuticals was founded in 2015.
-
Where is CStone Pharmaceuticals headquartered?
CStone Pharmaceuticals is headquartered in Suzhou, China.
-
What is the size of CStone Pharmaceuticals?
CStone Pharmaceuticals has 135 total employees.
-
What industry is CStone Pharmaceuticals in?
CStone Pharmaceuticals’s primary industry is Biotechnology.
-
Is CStone Pharmaceuticals a private or public company?
CStone Pharmaceuticals is a Public company.
-
What is CStone Pharmaceuticals’s stock symbol?
The ticker symbol for CStone Pharmaceuticals is 02616.
-
What is the current stock price of CStone Pharmaceuticals?
As of 22-Apr-2025 the stock price of CStone Pharmaceuticals is $0.36.
-
What is the current market cap of CStone Pharmaceuticals?
The current market capitalization of CStone Pharmaceuticals is $482M.
-
What is CStone Pharmaceuticals’s current revenue?
The trailing twelve month revenue for CStone Pharmaceuticals is $56.7M.
-
Who are CStone Pharmaceuticals’s competitors?
Alphamab Oncology, Abbisko Therapeutics, Innovent Biologics, BeiGene, and BoomRay Pharmaceuticals are some of the 12 competitors of CStone Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
